Anti-CD40 mAb treatment increased the percentage of CD11b+Gr1+ cells in the tumor draining lymph node in both the B16.F10 and T241 model, but co-treatment with sunitinib reversed the effect (Figure 3A-3B). Here, CD40 is linked to neoplasm.